dc.contributor.author | Pleguezuelos, Patricia | |
dc.contributor.author | Sibila, Marina | |
dc.contributor.author | Ramírez, Carla | |
dc.contributor.author | López-Jiménez, Rosa | |
dc.contributor.author | Pérez, Diego | |
dc.contributor.author | Huerta, Eva | |
dc.contributor.author | Llorens, Anna Maria | |
dc.contributor.author | Pérez, Mónica | |
dc.contributor.author | Correa-Fiz, Florencia | |
dc.contributor.author | Mancera Gracia, José Carlos | |
dc.contributor.author | Taylor, Lucas P. | |
dc.contributor.author | Smith, Jennifer | |
dc.contributor.author | Bandrick, Meggan | |
dc.contributor.author | Borowski, Stasia | |
dc.contributor.author | Saunders, Gillian | |
dc.contributor.author | Segalés, Joaquim | |
dc.contributor.author | Lopez-Soria, Sergio | |
dc.contributor.author | Fort, Maria | |
dc.contributor.author | Balasch, Mónica | |
dc.contributor.other | Producció Animal | ca |
dc.date.accessioned | 2023-02-13T15:07:53Z | |
dc.date.available | 2023-02-13T15:07:53Z | |
dc.date.issued | 2022-12-09 | |
dc.identifier.citation | Pleguezuelos, Patricia, Marina Sibila, Carla Ramírez, Rosa López-Jiménez, Diego Pérez, Eva Huerta, Anna Maria Llorens, Mónica Pérez, Florencia Correa-Fiz, José Carlos Mancera Gracia, Lucas P. Taylor, Jennifer Smith, Meggan Bandrick, Stasia Borowski, Gillian Saunders, Joaquim Segalés, Sergio López-Soria, Maria Fort and Mónica Balasch. 2022. "Efficacy Studies Against PCV-2 Of A New Trivalent Vaccine Including PCV-2A And PCV-2B Genotypes And Mycoplasma Hyopneumoniae When Administered At 3 Weeks Of Age". Vaccines 10 (12): 2108. doi:10.3390/vaccines10122108. | ca |
dc.identifier.issn | 2076-393X | ca |
dc.identifier.uri | http://hdl.handle.net/20.500.12327/2078 | |
dc.description.abstract | This study aimed to evaluate the efficacy of a new trivalent vaccine containing inactivated
Porcine Circovirus 1-2a and 1-2b chimeras and a Mycoplasma hyopneumoniae bacterin administered to
pigs around 3 weeks of age. This trivalent vaccine has already been proved as efficacious in a splitdose regimen but has not been tested in a single-dose scenario. For this purpose, a total of four studies
including two pre-clinical and two clinical studies were performed. Globally, a significant reduction
in PCV-2 viraemia and faecal excretion was detected in vaccinated pigs compared to non-vaccinated
animals, as well as lower histopathological lymphoid lesion plus PCV-2 immunohistochemistry
scorings, and incidence of PCV-2-subclinical infection. Moreover, in field trial B, a significant increase
in body weight and in average daily weight gain were detected in vaccinated animals compared to
the non-vaccinated ones. Circulation of PCV-2b in field trial A and PCV-2a plus PCV-2d in field trial B
was confirmed by virus sequencing. Hence, the efficacy of this new trivalent vaccine against a natural
PCV-2a, PCV-2b or PCV-2d challenge was demonstrated in terms of reduction of histopathological
lymphoid lesions and PCV-2 detection in tissues, serum and faeces, as well as improvement of
production parameters. | ca |
dc.format.extent | 22 | ca |
dc.language.iso | eng | ca |
dc.publisher | MDPI | ca |
dc.relation.ispartof | Vaccines | ca |
dc.rights | Attribution 4.0 International | ca |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | Efficacy Studies against PCV-2 of a New Trivalent Vaccine including PCV-2a and PCV-2b Genotypes and Mycoplasma hyopneumoniae When Administered at 3 Weeks of Age | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.description.version | info:eu-repo/semantics/publishedVersion | ca |
dc.rights.accessLevel | info:eu-repo/semantics/openAccess | |
dc.embargo.terms | cap | ca |
dc.subject.udc | 619 | ca |
dc.identifier.doi | https://doi.org/10.3390/vaccines10122108 | ca |
dc.contributor.group | Sanitat Animal | ca |